Biotechnology
Jobs at arGENX
About arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
- Industry
- Biotechnology
- Founded
- 2008
- Open roles
- 85
Open positions
Explore roles at arGENX
Showing 50 of 85 roles
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.
arGENX
arGENX is a global immunology company focused on developing and delivering medicines for patients with severe autoimmune diseases. Their pipeline includes differentiated assets like VYVGART, a first-in-class neonatal Fc receptor blocker.